Oncovita is a biotech company developing a disruptive virus-derived vaccine technology to treat multiple types of cancers. Our MeasovirTM platform was developed based on the safe and highly immunogenic measles virus vaccine, a vaccine with clinically proven oncolytic potential. This technology utilizes the natural anti-cancer and immunogenic properties of this harmless vaccine, making it a versatile platform to produce effective new cancer treatments and vaccines.
Over 10 years of intensive R&D activity has propelled Oncovita to bring forward our first therapeutic vaccine candidate, a genetically modified measles virus with enhanced immuno-oncolytic activity. Our in vitro and in vivo preclinical data demonstrate that this first candidate is active against many types of cancers such as mesothelioma, bladder cancer, ovarian cancer, multiple myeloma and others.
We believe that this therapy, based on a bioproduct derived from the safest human pediatric vaccine, will be widely accepted by patients and physicians. This technology will be part of the new and revolutionary generation of cancer treatments that should provide patients and medical doctors with treatment regimens that will not only have a positive impact on survival, but also on quality of life.